QuickLinks -- Click here to rapidly navigate through this document

Exhibit 10.68

License Agreement

        This License Agreement (the "Agreement") is entered into and made
effective as of March 29, 2002 (the "Effective Date"), between InterMune, Inc.,
("InterMune"); Marnac, Inc., ("Marnac"); KDL, Inc. and KDL GmBH (collectively,
"KDL"); Dr. Solomon Margolin ("Margolin"); and DR. Shitotomo Yamauchi
("Yamauchi"). Each party to this agreement may be referred to herein each as a
"Party" and all parties may be referred to jointly as the "Parties."

Recitals

        Whereas, InterMune is involved in the research, development and
commercialization of products potentially useful in the prevention, mitigation
and treatment of fibrotic and other diseases;

        Whereas, Marnac and KDL hold all ownership rights in that certain U.S.
Patent No. [*]; and corresponding foreign patents, including any and all
divisions, re-issues, continuations and substitutes in whole or in part of such
patents in the Territory (as defined below) with respect to [*] and directly
related Information; and

        Whereas, InterMune desires to obtain from Marnac and KDL, and Marnac and
KDL desire to grant to InterMune, the exclusive, [*] in the Territory for [*] of
Licensed Product.

        Now, therefore, in consideration of the foregoing recitals and the
mutual covenants and agreements contained herein, the Parties hereby agree as
follows:

1.     Definitions

        1.1    "Acceptance"    as used in this Agreement, shall mean acceptance
by the appropriate governing authority as being filed in correct form, rather
than as signifying regulatory approval.

        1.2    "Affiliate"    means any company or entity controlled by,
controlling or under common control with a Party. As used in this Section 1.1,
"control" means (a) that an entity or company owns, directly or indirectly, more
than fifty percent (50%) of the voting stock of another entity, or (b) that an
entity, person or group has the actual ability to control and direct the
management of the entity, whether by contract or otherwise.

        1.3    "Best Efforts"    means every necessary and prudent effort of a
Party applied in a prompt, commercially reasonable manner.

        1.4    "Commercially Reasonable Business Practice"    means making
efforts and devoting resources that a similarly situated biopharmaceutical
company would typically devote to a product of similar market potential, profit
potential or strategic value, based on conditions then prevailing.

        1.5    "Information"    means information, results and data of any type
whatsoever, in any tangible or intangible form, including without limitation
inventions, practices, methods, techniques, specifications, formulations,
formulae, knowledge, know-how, skill, experience, trade secrets, test data
(including pharmacological, biological, chemical, biochemical, toxicological and
clinical test data), analytical and quality control data, stability data,
studies and procedures, all filings made to Regulatory Agencies, and patent and
other legal information or descriptions, and all intellectual property rights
therein, all limited to the anti-fibrotic application of Pirfenidone.

        1.6    "First Sale"    means the first commercial sale of Licensed
Product.

        1.7    "IND"    shall have the meaning given in Section 6.2.

        1.8    "Licensed Patents"    means [*] the Territory, including any and
all divisions, re-issues, re-examinations, renewals, continuations and
substitutes in whole or in part of such patents and patent applications in the
Territory with respect to [*] and all Patents (as defined in 1.13). The Licensed
Patents shall specifically [*]

--------------------------------------------------------------------------------

[*]CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

--------------------------------------------------------------------------------

        1.9    "Licensed Product"    means a product that [*] for the
therapeutic treatment of [*] which product has [*] for the therapeutic treatment
of [*] by the [*] through the [*]

        1.10    "Net Sales"    means, with respect to any Licensed Product, [*]

        (a)   [*]

        (b)   [*]

        (c)   [*]

        (d)   [*]

        (e)   [*]

        (f)    [*]

        A sale of a Licensed Product shall be deemed to occur upon [*]

        1.11    "Ongoing Clinical Trials"    shall have the meaning given in
Section 6.2.

        1.12    "Orphan Drug Status"    is an exclusive approval to market a
therapeutic for the treatment of a human fibrotic disease based upon orphan drug
status under the Orphan Drug Act of 1983 in the United States (Pub.L. 97-414,
Jan.4, 1983, 96 Stat. 2049) or any corresponding or similar non-U.S. statutes,
granted by the U.S. Food and Drug Administration ("FDA"), the Committee on
Proprietary Medicinal Products ("CPMP") or other Regulatory Agencies in the
Territory to InterMune for the anti-fibrotic uses of Pirfenidone for such
disease.

        1.13    "Patents"    means all of Marnac's, KDL's, Margolin's and
Yamauchi's (a) [*] patent applications heretofore or hereafter filed or having
legal force in any country including without limitation divisionals,
continuations, continuation-in-part and provisional applications; (b) issued,
unexpired [*] patents in any country, including utility, model and design
patents and certificates of invention; and (c) substitutions, extensions,
reissues, renewals, and supplementary protection certificates with respect to
any such issued patents. For clarity, such patent applications and patents shall
include those owned, as well as those controlled with the right to grant
licenses, by any of Marnac, KDL, Margolin and Yamauchi. The Patents shall [*]

        1.14    "Permitted Seller"    means InterMune and its Affiliates and any
permitted assignee, licensee or sublicensee having the right to sell Product
hereunder.

        1.15    "Pirfenidone"    shall mean [*]

        1.16    "Regulatory Agencies"    means the FDA, the CPMP, and other
governmental agencies having similar jurisdiction over the development,
manufacturing, and marketing of pharmaceuticals.

        1.17    "Territory"    means worldwide (excluding Japan, Taiwan and
Korea).

        1.18    "Third Party"    means any party other than InterMune and Marnac
and their respective Affiliates, and other than KDL, Margolin and Yamauchi.

        1.19    "Valid Claim"    means a claim of an issued and unexpired
Licensed Patent in a country which claim: (i) but for this Agreement, would
preclude the sale of [*] by InterMune or another seller, (ii) has not been
revoked or held unenforceable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within
the time allowed for appeal, and (iii) has not been abandoned, disclaimed or
admitted to be invalid or unenforceable through reissue, disclaimer or
otherwise.

2.     Grant of License

        2.1    Grant to InterMune.    Subject to Section 2.2, Marnac and KDL
hereby grant to InterMune an exclusive [*] license in the Territory under the
Licensed Patents and Information for [*] Licensed Products.

--------------------------------------------------------------------------------

[*]CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

--------------------------------------------------------------------------------

        2.2    Research and Clinical Development.    [*] may conduct [*]
relating to the [*] but shall not, under any conditions, [*] relating to the [*]
the prior written consent of [*]

3.     Consideration

        3.1    Initial Payment.    Within five (5) business days after the
Effective Date, InterMune shall pay to Marnac Eighteen Million Seven Hundred and
Fifty Thousand Dollars ($18,750,000) in cash.

        3.2    Milestone Payments.    InterMune shall make the following
milestone payments to Marnac, within [*] days of achieving these milestones:

        (a)   [*]

        (b)   [*]

        (c)   [*]

        (d)   [*] and

        (e)   [*]

[*]

3.3   Royalties.

        (a)   InterMune shall pay to Marnac a royalty of [*] on Net Sales of all
Licensed Products in the Territory calculated by U.S. generally accepted
accounting principles ("GAAP").

        (b)   If InterMune [*] InterMune shall pay a royalty to Marnac at the
rate of [*] of Net Sales on such sales for the [*] in such country.

        (c)   InterMune's obligations pursuant to this Section 3.3 to pay
royalties shall expire with respect to Net Sales for Licensed Products approved
for particular indications with the expiration of this Agreement with respect
thereto as set forth in Section 10.1.

        3.4    Payments to Marnac and KDL.    With respect to any dollar amounts
that InterMune is required to pay in dollars hereunder pursuant to Section 3.1,
3.2 or 3.3, InterMune shall make such payment [*] notifies InterMune no later
than [*] business days before such payment is due in writing as to whom
InterMune must pay. If [*] business days before any such payment is due
hereunder, then InterMune shall [*]

        3.5    Payment of Royalties.    Following the First Sale of a Licensed
Product and during the term of the Agreement, InterMune shall furnish to Marnac
a quarterly written report for each calendar quarter showing the sales of all
Licensed Products subject to royalty payments hereunder during the reporting
period and the royalties payable under this Agreement. Reports shall be due
within [*] days following the close of each calendar quarter. Royalties that
have accrued in a particular calendar quarter shall be due and payable on the
date such royalty report is due. InterMune shall keep complete and accurate
records in sufficient detail to enable the royalties payable hereunder to be
determined.

--------------------------------------------------------------------------------

[*]CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

--------------------------------------------------------------------------------

        3.6    Records and Audit.    InterMune shall maintain the records used
to calculate all royalties payable under Section 3.3(a) and 3.3(b), including,
without limitation, all records which support the calculation of each component
of the equation for Net Sales. Such records shall be maintained for at least [*]
years following the end of the calendar year to which they pertain. Such records
will be open for audit during such [*] period by an independent certified public
accountant selected by Marnac and KDL and reasonably acceptable to InterMune for
the purpose of verifying InterMune's royalty and Net Sales calculations. Such
audits may be made no more than once each calendar year, at reasonable times
mutually agreed by InterMune, Marnac and KDL. Marnac and KDL shall bear the
costs and expenses of audits conducted under this Section 3.6 unless a variation
or error producing an underpayment in royalties payable exceeding [*] of the
amount payable for the time period inspected is established in the course of any
such audit, whereupon all costs relating to the audit and any unpaid amounts
that are discovered will be paid by InterMune, together with interest on such
unpaid amounts equal to the lesser of [*] per year, or the maximum rate
permitted by law. Should the inspection prove overpayment by InterMune, such
overpayment shall be deducted from the next royalty or other payment due from
InterMune hereunder, without any interest due by Marnac and KDL. If [*] then the
Parties agree that [*]

        All information obtained during and resulting from such audits conducted
according to this Section 3.6 are hereby deemed Confidential Information as such
term is defined in Section 8.1 and shall be kept confidential pursuant to
Section 8.1.

        3.6    Income Tax Withholding.    If laws, rules or regulations require
withholding of income taxes or other taxes imposed upon payments set forth in
this Section 3, InterMune shall make such withholding payments as required and
subtract such withholding payments from the payments set forth in this
Section 3. InterMune shall submit appropriate proof of payment of the
withholding taxes to Marnac or KDL, as appropriate, within a reasonable period
of time.

4.     Manufacturing and Supply.

        4.1    [*].    Marnac shall [*] including but not limited to the [*]
associated with the [*] Marnac shall [*] InterMune. InterMune shall be
responsible for [*] or such other [*]

        4.2    [*] Supply.    

        (a)   [*] of Licensed Product [*] in accordance with [*] that as of the
[*] to which InterMune [*] adequate to permit [*] conducting such [*] for which
[*] days of receipt of such [*] shall provide to [*] of Licensed Product, [*] of
Licensed Product. [*] the Effective Date.

        (b)   [*] agrees to [*] to use to [*] and other [*] of such quantities
[*] Licensed Product or [*] InterMune agrees to [*]

        (c)   [*] shall provide to [*]

5.     InterMune Development and Commercialization Obligations.

        5.1    [*].    InterMune shall [*]

        5.2    Development and Commercialization.    

        (a)   InterMune shall, [*] assuming that the [*] to support the [*] In
the event that [*] is sufficiently [*] and InterMune [*] InterMune will [*] set
forth in Sections [*]

        (b)   InterMune shall also, [*] In the event that [*] InterMune will [*]
set forth in Sections [*]

        (c)   For purposes of Sections [*] in the context of those paragraphs.

--------------------------------------------------------------------------------

[*]CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

--------------------------------------------------------------------------------

6.     Marnac and Margolin Obligations

        6.1    Information.    Marnac and Margolin shall deliver to InterMune,
within [*] Information in Marnac's or in Margolin's possession, including but
not limited to: a list of Licensed Patents; any Information relating to the
Licensed Patents, the [*] of Licensed Product; provided that, if Marnac or
Margolin [*] of the Information and shall [*] for InterMune. InterMune
acknowledges that the [*] that they have [*] With respect to such [*] the
Parties agree that [*] shall not be required to [*] shall reasonably cooperate
with [*] to the extent reasonably requested by [*] in relation to any [*]

        6.2    [*]    

        (a)   [*] Exhibit B contains [*] relating to [*] having a similar [*] of
the Territory [*] with their cooperation [*] as of the [*] and (ii) all [*] for
any [*] pursuant to the [*] as of the [*] after the [*] shall make [*] as to any
[*] having a similar [*] of the Territory for the [*] and any [*] relating to
such [*] in the Territory, and [*] During the period commencing on [*] and
ending [*] thereafter, [*] shall provide: (i) [*] to any of the [*] (which
relate to [*]) as may be reasonably [*] relating to [*] and/or to [*]; (ii) [*];
(iii) [*] upon reasonable advance notice, to [*]; and (iv) [*] in other aspects
of [*] of Licensed Product. Such [*] shall include, without limitation, that [*]
with each [*] that InterMune requests to [*] which shall include [*] if required
for [*]

        (b)   [*] shall be entitled, to [*] in connection with [*] (which are
for [*]). [*] shall be responsible for [*] in connection with the [*] to the
extent that [*] from any such [*] from and after the [*] In the event that [*]
with any particular [*] for which [*] resulting from such [*] With respect to
the [*] from any [*] in such [*] (other than to the extent [*]) prior to [*]

        6.3    [*].    [*] prior written consent, which consent shall not be
unreasonably withheld, for any [*] relating to the [*] The Parties recognize
that for the [*] that are [*] of the Effective Date, and certain [*] of the
Effective Date (collectively, such [*] pursuant to [*] regarding the [*] To the
extent that [*] relating to any [*] the right to [*] to exercise such right in
accordance with [*] The Parties recognize the [*] of one or more of [*]
regarding an [*] to this arrangement, subject only to [*] with respect to such
[*] as set forth in this Section 6.2. [*] as Exhibit C to this Agreement is a
[*] as defined above in this Section 6.3.

        6.4    [*].    The Parties recognize that a [*] shall provide [*] shall
continue to [*] on the same basis the basis upon which [*] provided that [*] as
warranted by [*] shall have the right in its sole discretion to [*] in the
future shall be [*] to InterMune.

7.     Intellectual Property Matters; Patents.

        7.1    Ownership.    InterMune shall solely own any Information invented
or developed in connection with any Licensed Product and all intellectual
property rights therein, including without limitation any patents claiming such
Information.

        7.2    Control and Prosecution.    InterMune shall be responsible for
and control all patent filings, and prosecute and maintain any patents,
divisions, continuations with respect to the Licensed Patents in the Territory;
provided, however, that InterMune shall provide Marnac with prior notice and
opportunity to review and comment on any action taken by InterMune in
controlling such Licensed Patents. Marnac and KDL on the one hand, and InterMune
on the other hand, shall [*] Marnac and KDL shall be [*]

        7.3    Cooperation.    Each Party agrees to cooperate with the other and
take all reasonable additional actions as may be reasonably required to achieve
the intent of this Section 7, including, without limitation, the execution of
necessary and appropriate instruments and documents.

--------------------------------------------------------------------------------

[*]CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

--------------------------------------------------------------------------------

        7.4    Infringement of Third Party Patents.    In the event that a Third
Party files an action against a Party alleging that such Party's activities
under this Agreement infringe such Third Party's patent rights, such Party shall
give written notice to the other Party, and the Parties will consult and
cooperate on the best course of action. The Party that was sued shall have the
right to defend itself against such action, and the other Party shall provide
all reasonable assistance in such defense.

        7.5    Infringement of Licensed Patents.    If any Party becomes aware
that a Third Party is infringing any rights in the Licensed Patents, such Party
shall give written notice to the other Party describing in detail the nature of
such infringement. InterMune shall have the initial right to enforce the
Licensed Patents against such Third Party infringer. Marnac and KDL agree to
provide InterMune all reasonable assistance, [*] in such enforcement, including
without limitation being joined as a party to the suit where appropriate. In the
event that InterMune fails to institute an infringement suit or take other
reasonable action in response to such infringement within [*] after its receipt
of notice of such infringement, Marnac shall have the right, but not the
obligation, to institute such suit or take other appropriate action in its own
name to enforce the Licensed Patents. Any damages or other recovery, whether by
settlement or otherwise, from an action hereunder to enforce the Licensed
Patents shall first be applied to pay the costs and expenses of participating in
such action, and any remaining amount shall be shared by the Parties as follows:
(i) if InterMune institutes the infringement suit, [*] shall be paid to Marnac
and the remainder shall be paid to InterMune, and (ii) if Marnac or KDL
institutes the infringement suit because InterMune fails to institute an
infringement suit or take other reasonable action in response to such
infringement, [*] shall be paid to Marnac and the remainder shall be paid to
InterMune.

        7.6    New Inventions.    [*] shall be subject to [*] set forth in
Section [*] without the prior written consent of [*] Nothing in this paragraph
shall affect, limit, or restrict in any way [*]

8.     Confidentiality

        8.1   The Parties incorporate into this Agreement the Mutual
Confidential Disclosure Terms, attached as Exhibit A (the "CDA"), and
"Confidential Information" has the meaning given therein.

        8.2   InterMune will issue a press release concerning the Parties' entry
into this Agreement, with the contents of such release to be approved in writing
in advance by Marnac, which approval shall not be unreasonably withheld. Except
as required by law, none of the Parties shall publicly disclose the terms and
conditions of this Agreement unless expressly authorized in writing to do so by
the other Party, which authorization shall not be unreasonably withheld.

9.     Representations and Warranties

        9.1    Mutual Representations and Warranties.    Each Party hereby
represents and warrants to each other Party that:

        (a)   it has full corporate or personal power and authority under the
laws of the state or country of its incorporation to enter into this Agreement
and to carry out the provisions hereunder;

        (b)   this Agreement is a legal and valid obligation binding upon it and
is enforceable in accordance with its terms;

        (c)   the execution, delivery and performance of this Agreement by it
does not materially conflict with any agreement, oral or written, to which it is
a party or by which it may be bound, nor violate any law or regulation of any
court, governmental body or administrative or other agency having authority over
it; and

        (d)   [*]

--------------------------------------------------------------------------------

[*]CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

--------------------------------------------------------------------------------

        9.2    Additional Representations and Warranties.    Marnac, KDL,
Margolin and Yamauchi each hereby represents and warrants to InterMune that:

        (a)   Marnac owns or has the right to represent all the owners of the
Licensed Product;

        (b)   None of the claims in the Licensed Patents have been
misappropriated from any Third Party nor are the result of any misuse of any
Third Party's intellectual property;

        (c)   All inventors of the Licensed Patents have irrevocably assigned
all right, title and interest in the Licensed Patents to Marnac and/or KDL;

        (d)   InterMune's practice of the claims under the Licensed Patents will
not infringe the rights of any Third Party;

        (e)   No claim, whether or not embodied in an action past or present, of
any infringement, of any conflict with, or of any violation of any patent, trade
secret or other intellectual property right or similar right of any Third Party,
has been made or is pending or threatened with respect to the Licensed Patents;
and

        (f)    This Agreement does not conflict with any other agreement to
which Marnac, KDL, Margolin or Yamauchi is a party, and none of them shall enter
into an agreement during the term of this Agreement that is in conflict with
this Agreement.

        9.3     Additional Representation and Warranty.    [*] further
represents and warrants that to the best of its knowledge, the [*] as well as
the [*] and that to the best of their knowledge, any [*] Nothing in the
representation and warranty in the preceding sentence is intended to warrant the
[*] Rather such warranty and representation is limited to a warranty and
representation that, to the best of [*] and, to the best of [*] knowledge, the
[*]

        9.4    Disclaimer.    Aside from the representations and warranties made
by the Parties expressly in this Agreement, EACH PARTY HEREBY DISCLAIMS ANY
IMPLIED WARRANTY AS TO THE LEGAL EFFECT OF THE LICENSED PATENTS, THE FITNESS OF
THE LICENSED PATENTS FOR THEIR INTENDED PURPOSE, THE MERCHANTABILITY OF THE
LICENSED PATENTS, AND ALL OTHER WARRANTIES WHICH MAY BE IMPLIED AT LAW. THE
LICENSED PATENTS ARE LICENSED "AS IS" WITHOUT WARRANTY OTHER THAN WARRANTIES OF
TITLE AND WARRANTIES EXPRESSLY SET OUT IN THIS AGREEMENT.

        This disclaimer of warranty, however, shall not disclaim: (i) the
implied contractual covenant of good faith and fair dealing, which the Parties
hereby expressly recognize as applicable to this Agreement; (ii) the express and
implied duties of the Parties to perform as set forth herein; and (iii) any
warranty which may not be disclaimed as a matter of patent or other existing
law.

        9.5    Indemnity.    Each Party to this Agreement shall defend,
indemnify and hold harmless the other Parties (and their directors, officers,
employees and agents) against any liability or damages from any claims of any
Third Party to the extent that such claims arise from a material breach by the
indemnifying Party(ies) of any of his or its representations or warranties
contained herein.

10.   Term and Termination.

        10.1    Term.    The term of this Agreement shall commence on the
Effective Date and expire upon the later of (a) the expiration of U.S. Patent
[*]; and (b) on a disease-by-disease and country-by-country basis (as determined
by reference to the indications for which Pirfenidone is approved in such
country), the later of (i) in the event that Orphan Drug Status is granted, the
expiration of market exclusivity that results from the Orphan Drug Status for
such disease in such country, and (ii) the expiration of the last Valid Claim
claiming the use of Pirfenidone to treat such disease in such country, after
which expiration of this Agreement, InterMune shall have a fully paid-up,
royalty-free, perpetual, irrevocable, sublicenseable license to the Licensed
Patents and Information.

        10.2    Termination by InterMune.    InterMune may terminate this
Agreement upon [*] days' written notice to Marnac.

--------------------------------------------------------------------------------

[*]CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

--------------------------------------------------------------------------------

        10.3    Termination for Material Breach.    If a Party materially
breaches this Agreement, and within [*] days of written notice of breach from
the non-breaching Party, the breaching Party has not (i) cured the breach or
(ii) initiated good faith efforts to cure such breach to the reasonable
satisfaction of the non-breaching Party, then the non-breaching Party may
terminate this Agreement in writing promptly after expiration of such [*] day
period.

        10.4    Effect of Termination.    

        (a)   In the event that InterMune terminates this Agreement pursuant to
Section 10.2, or Marnac terminates this Agreement pursuant to Section 10.3, the
license granted to InterMune pursuant to Section 2.1 shall immediately
terminate.

        (b)   In the event that Marnac or KDL materially breach this Agreement,
InterMune shall have the right to seek specific performance of this Agreement,
in lieu of termination. The Parties agree that InterMune may not have an
adequate remedy at law in the event of any material breach that interferes with
InterMune's ability to commercially develop those rights licensed in this
Agreement.

        10.5    Bankruptcy Rights.    In the event that this Agreement is
terminated or rejected by a Party or its receiver or trustee under applicable
bankruptcy laws due to such Party's bankruptcy, then all rights and licenses
granted under or pursuant to this Agreement by such Party to the other Party
are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the
Bankruptcy Code and any similar law or regulation in any other country, licenses
of rights to "intellectual property" as defined under Section 101(52) of the
Bankruptcy Code. The Parties agree that all intellectual property rights
licensed hereunder, including without limitation any patents or patent
applications of a Party in any country covered by the license grants under this
Agreement, are part of the "intellectual property" as defined under
Section 101(52) of the Bankruptcy Code subject to the protections afforded the
non-terminating Party under Section 365(n) of the Bankruptcy Code, and any
similar law or regulation in any other country.

11.   Miscellaneous

        11.1    Entire Agreement; Amendment.    This Agreement and the CDA set
forth the complete, final and exclusive agreement between the Parties with
respect to the subject matter hereof, and all of the covenants, promises,
agreements, warranties, representations, conditions and understandings between
the Parties hereto with respect to such subject matter, and supersedes and
terminates all prior agreements and understandings between the Parties with
respect to such subject matter. There are no covenants, promises, agreements,
warranties, representations, conditions or understandings, either oral or
written, between the Parties with respect to such subject matter other than as
are set forth herein and therein. No subsequent alteration, amendment, change or
addition to this Agreement shall be binding upon the Parties unless reduced to
writing and signed by the Party, if an individual, or an authorized officer of
each Party.

        11.2    Force Majeure.    The Parties shall be excused from the
performance of their obligations under this Agreement to the extent that such
performance is prevented by force majeure and the non-performing Party promptly
provides notice of the prevention to the other Party. Such excuse shall be
continued so long as the condition constituting force majeure continues and the
non-performing Party takes reasonable efforts to remove the condition. For
purposes of this Agreement, "force majeure" shall include conditions beyond the
control of the Parties, including without limitation, an act of God, voluntary
or involuntary compliance with any regulation, law or order of any government,
war, civil commotion, labor strike or lock-out, epidemic, failure or default of
public utilities or common carriers, destruction of production facilities or
materials by fire, earthquake, storm or similar catastrophe.

--------------------------------------------------------------------------------

[*]CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

--------------------------------------------------------------------------------

        11.3    Notices.    Any notice required or permitted to be given under
this Agreement shall be in writing, shall specifically refer to this Agreement
and shall be deemed to have been sufficiently given for all purposes if mailed
by first class certified or registered mail, postage prepaid, express delivery
service or personally delivered, or if sent by facsimile and confirmed through
one of the foregoing methods. Unless otherwise specified in writing, the mailing
addresses of the Parties shall be as described below.

 
   
For InterMune:   InterMune, Inc.
3280 Bayshore Boulevard
Brisbane, CA 94005
Fax: (415) 508-0006
Attention: General Counsel
For Marnac:
 
Marnac, Inc.
9400 N. Central Expressway, Suite 305
Dallas, TX 75231
Fax: (214) 692-8510
Attention: Solomon B. Margolin
For Margolin:
 
Marnac, Inc.
9400 N. Central Expressway, Suite 305
Dallas, TX 75231
Fax: (214) 692-8510
Attention: Solomon B. Margolin
For KDL:
 
KDL GmbH
Bahnhof Strasse 11
CH-6301 Zug
Switzerland
Attention: Dr. Shitotomo Yamauchi
For Yamauchi:
 
KDL GmbH
Bahnhof Strasse 11
CH-6301 Zug
Switzerland
Attention: Dr. Shitotomo Yamauchi
With a copy to:
 
Robert H. Nunnally, Jr.
Wisener*Nunnally, LLP
620 West Main Street
Garland, Texas 75040
Facsimile: (972) 205-9421

        11.4    Independent Contractors.    The status of the Parties under this
Agreement shall be that of independent contractors. Neither Party shall have the
right to enter into any agreements on behalf of the other Party, nor shall it
represent to any person that it has any such right or authority. Nothing in this
Agreement shall be construed as establishing a partnership or joint venture
relationship between the Parties.

        11.5    Maintenance of Records.    Each Party shall keep and maintain
all records required by law or regulation with respect to the Product and shall
make copies of such records available to the other Party upon request.

        11.6    United States Dollars.    References in this Agreement to
"Dollars" or "$" shall mean the legal tender of the United States of America.

--------------------------------------------------------------------------------

[*]CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

--------------------------------------------------------------------------------

        11.7    No Strict Construction.    This Agreement has been prepared
jointly and shall not be strictly construed against any Party. This Agreement
shall be construed liberally to accomplish the Parties' objectives set forth in
this Agreement.

        11.8    Assignment.    Neither Party may assign or transfer this
Agreement or any rights or obligations hereunder without the prior written
consent of the other; provided however, a Party may make such an assignment
without the other Party's consent to a successor-in-interest to substantially
all of the business assets of such Party to which this Agreement relates,
whether in a merger, sale of stock, sale of assets or other transaction. Any
permitted successor or assignee of rights and/or obligations hereunder shall, in
a writing to the other Party, expressly assume performance of such rights and/or
obligations. This Agreement shall be binding upon and shall inure to the benefit
of each Party's successors-in-interest and permitted assigns. Any assignment or
attempted assignment by either Party in violation of the terms of this
Section 10 shall be null and void and of no legal effect.

        11.9    Counterparts.    This Agreement may be executed in two or more
counterparts, and by facsimile, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument.

        11.10    Further Actions.    Each Party agrees to execute, acknowledge
and deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

        11.11    Severability.    If any one or more of the provisions of this
Agreement is held to be invalid or unenforceable, the provision shall be
considered severed from this Agreement and shall not serve to invalidate any
remaining provisions hereof. The Parties shall make a good faith effort to
replace any invalid or unenforceable provision with a valid and enforceable one
such that the objectives contemplated by the Parties when entering this
Agreement may be realized.

        11.12    Ambiguities.    Ambiguities, if any, in this Agreement shall
not be construed against any Party, irrespective of which Party may be deemed to
have authored the ambiguous provision.

        11.13    Headings.    The headings for each article and section in this
Agreement have been inserted for convenience of reference only and are not
intended to limit or expand on the meaning of the language contained in the
particular article or section.

        11.14    No Waiver.    Any delay in enforcing a Party's rights under
this Agreement or any waiver as to a particular default or other matter shall
not constitute a waiver of such Party's rights to the future enforcement of its
rights under this Agreement, excepting only as to an express written and signed
waiver as to a particular matter for a particular period of time.

        11.15    Choice of Law; Jurisdiction; Venue.    This Agreement will be
governed and construed in accordance with the laws of the State of Colorado as
applied to transactions taking place wholly within Colorado between Colorado
residents. For any legal action arising from or related to this Agreement, the
Parties hereby: (i) consent and submit solely to jurisdiction and venue of the
state and federal courts located in Denver, Colorado, (ii) agree that such
courts shall be the sole courts utilized and (iii) hereby waive any
jurisdictional or venue objections to such courts, including without limitation,
forum non conveniens.

        11.16    Litigation Costs.    If any dispute arises between the Parties
with respect to the matters covered by this Agreement which leads to a
proceeding to resolve such dispute, the prevailing Party in such proceeding
shall, upon a finding by the Court that the non-prevailing Party's position
lacked substantial merit, be entitled to receive its reasonable attorneys' fees,
expert witness fees and out-of-pocket costs incurred in connection with such
proceeding, in addition to any other relief it may be awarded.

--------------------------------------------------------------------------------

[*]CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

--------------------------------------------------------------------------------

        11.17    Injunctive Relief.    A breach of any of the promises or
agreements contained in Section 8 of this Agreement may result in irreparable
and continuing damage to a Party for which there may be no adequate remedy at
law, and each Party is therefore entitled to seek injunctive relief as well as
such other and further relief as may be appropriate. The obligations provided
under Section 8 of this Agreement are acknowledged as necessary and reasonable
in order to protect each Party and its business, and each Party expressly agrees
that monetary damages would be inadequate to compensate the other Party for the
breach thereof. Accordingly, each Party agrees and acknowledges that any such
violation or threatened violation will cause irreparable injury to the other
Party and that, in addition to any other remedies that may be available, in law,
in equity or otherwise, each Party shall be entitled to obtain injunctive relief
against the breach or threatened breach by the other Party of Section 8 of this
Agreement, without the necessity of proving actual damages.

        In Witness Whereof, the Parties have executed this Agreement in by their
proper officers as of the date and year first above written.

InterMune, Inc.   Marnac, Inc. By: /s/  JOHN J. WULF      

--------------------------------------------------------------------------------

  By: /s/  SOLOMON B. MARGOLIN      

--------------------------------------------------------------------------------

 
 
   
 
Print Name: John J. Wulf

--------------------------------------------------------------------------------

  Print Name: Solomon B. Margolin

--------------------------------------------------------------------------------

 
 
   
 
Title: Sr. Vice President of Corporate Development

--------------------------------------------------------------------------------

  Title: President

--------------------------------------------------------------------------------

 
 
   
 
KDL, Inc.   Dr. Solomon Margolin By: Marnac, Inc., its attorney in fact  
/s/  SOLOMON B. MARGOLIN      

--------------------------------------------------------------------------------

/s/  SOLOMON B. MARGOLIN      

--------------------------------------------------------------------------------

Dr. Solomon B. Margolin, President      

 
 
   
 
SHITOTOMO YAMAUCHI   KDL GmbH /s/  SOLOMON B. MARGOLIN      

--------------------------------------------------------------------------------

  /s/  SOLOMON B. MARGOLIN      

--------------------------------------------------------------------------------

By: Marnac, Inc., his attorney in fact   By: Marnac, Inc., its attorney in fact
Dr. Solomon B. Margolin, President   Dr. Solomon B. Margolin, President

--------------------------------------------------------------------------------

[*]CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

--------------------------------------------------------------------------------

Exhibit A—Mutual Confidentiality and Disclosure Agreement

        The Parties to the License Agreement are bound by the following further
provisions, which are set out as an exhibit for sake of clarity and convenience:

        1.     The Parties wish to exchange information in connection with
InterMune's licensing of Pirfenidone from Marnac through the License Agreement,
which will entail the exchange of certain confidential information relating to
Marnac's proprietary information, products and/or business ("Marnac Confidential
Information") and/or InterMune's proprietary information, products and/or
business ("InterMune Confidential Information"). (The Marnac Confidential
Information and the InterMune Confidential Information are referred to
collectively as "Confidential Information.") This Agreement shall govern the
disclosure of the Confidential Information.

        2.     For purposes of this Agreement, the party that transmits
Confidential Information shall be referred to as the "Discloser," and the party
to which Confidential Information is transmitted shall be referred to as the
"Recipient." [*] subject to the [*]

        3.     InterMune hereby agrees not to use the Marnac Confidential
Information except as the Parties may agree, and all data and results from such
discussions shall be protected as confidential pursuant to this Agreement.

        4.     Marnac hereby agrees not to use the InterMune Confidential
Information except as the Parties may agree, and all data and results from such
discussions shall be protected as confidential pursuant to this Agreement.

        5.     Each Party agrees that, as a Recipient, the Party will use the
same degree of care to keep all Confidential Information confidential as the
Party uses with respect to its own information of similar importance. Unless
Recipient first obtains the Discloser's written consent, Recipient shall not
disclose any Confidential Information to others, except to the licensees,
employees or agents of Recipient who reasonably require the Confidential
Information for the purpose of this Agreement and who will use the Confidential
Information only for that purpose.

        6.     Marnac and KDL warrant that they will not reveal any InterMune
Confidential Information to any licensee, employee, contactor or agent of Marnac
without first informing that licensee, employee, contractor or agent of the
confidential nature of the InterMune Confidential Information and securing the
licensee's, employee's, contractor's or agent's agreement to be bound by terms
and conditions substantially equivalent to those in this Agreement as they apply
to Marnac.

        7.     InterMune warrants that it will not reveal any Marnac
Confidential Information to any licensee, employee, contractor or agent of
InterMune without first informing that licensee, employee, contractor or agent
of the confidential nature of the Marnac Confidential Information and securing
the licensee's, employee's, contractor's or agent's agreement to be bound by
terms and conditions substantially equivalent to those in this Agreement as they
apply to InterMune.

--------------------------------------------------------------------------------

[*]CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

--------------------------------------------------------------------------------

        8.     Notwithstanding anything to the contrary in this Agreement,
Recipient shall not be prevented from using or disclosing Confidential
Information that:

        (a)   Recipient can demonstrate by competent proof was lawfully known to
Recipient before the disclosure by the Discloser and not obtained or derived
directly or indirectly from Discloser;

        (b)   is now, or becomes in the future, public knowledge other than by
through the act or default of Recipient or its employees;

        (c)   Recipient obtains from a source independent of Discloser who is
lawfully in possession of such Confidential Information and is not subject to an
obligation of confidentiality or non-use owed to Discloser;

        (d)   Recipient can demonstrate or prove was independently developed by
Recipient without use or knowledge of such Confidential Information; or

        (e)   is properly required by law, regulation, rule, act or order of any
governmental authority or agency to be disclosed by Recipient, provided that
Recipient shall provide Discloser with reasonable advance notice of any such
required disclosure and cooperate with Discloser in minimizing the extent of any
such disclosure and in seeking such protective order(s) or the like as may be
available to protect the confidentiality of the Confidential Information; and
provided further that Recipient will make such disclosure only to the extent the
disclosure is legally required.

        Recipient further agrees that, if any Confidential Information becomes
subject to the exceptions set forth in this Section 8, Recipient will not
disclose that such information was received from and/or is used by Discloser
unless such fact also becomes part of the public domain.

        Notwithstanding any other provision in this Agreement, InterMune may use
or disclose Marnac Confidential Information in connection with the filing or
publication of any patent or patent application desired by InterMune to the
extent such use or disclosure is necessary to support the patent or patent
application.

        9.     The receipt of Confidential Information shall not be deemed an
admission by the Recipient of the novelty or patentability of said subject
matter. Nothing in this Agreement, or in the furnishing of Confidential
Information by the Discloser, shall be construed as giving Recipient any right,
title, interest in or ownership of Confidential Information which is or becomes
covered by any patents, copyrights, trademarks, trade secrets or know-how owned
or held by the Discloser.

        10.   Each Recipient's confidentiality and non-use obligations under
this Agreement shall remain in effect for [*] after the expiration or
termination of the License Agreement.

        11.   If this Agreement is terminated pursuant to Sections 10.2 or 10.3
of the License Agreement, then each Party shall return all tangible Confidential
Information (including any samples) to Discloser, except that the Recipient
shall have the right to retain one (1) record copy of such tangible Confidential
Information in its legal files, from which to ascertain Recipient's continuing
obligations to the Discloser under this Agreement.

--------------------------------------------------------------------------------

[*]CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

--------------------------------------------------------------------------------

Exhibit B

[*]

--------------------------------------------------------------------------------

[*]CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

--------------------------------------------------------------------------------

Exhibit C

Other Trials (as defined in Section 6.3)

        [*]

--------------------------------------------------------------------------------

[*]CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

--------------------------------------------------------------------------------

QuickLinks

Exhibit 10.68

License Agreement
Recitals
Exhibit A—Mutual Confidentiality and Disclosure Agreement
Exhibit B
Exhibit C
Other Trials (as defined in Section 6.3)